Main | MinervaX announces results from Phase I clinical trial »
Monday
Jan212019

MinervaX announces investment of 4.4 mEUR

MinervaX announces award of 4.4 mEUR in investment from Novo Holding's REPAIR Impact Fund and Sunstone Life Science Ventures for further clinical development of the company's vaccine against Group B Streptococcus.



Press release